teprotumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 5387 1036734-93-6

Description:

MoleculeDescription

Synonyms:

  • teprotumumab
  • teprotumumab-trbw
  • tepezza
  • RO4858696-000
  • R 1507
  • RG 1507
Teprotumumab-trbw’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2020 FDA HORIZON THERAPEUTICS IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasms 149.68 63.00 56 560 125497 50479011
Hypoacusis 72.54 63.00 21 595 20626 50583882

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasms 91.63 62.63 34 379 140989 64357330

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA53 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA EPC N0000193926 Insulin-like Growth Factor-1 Receptor Inhibitor
FDA MoA N0000193927 Insulin-like Growth Factor-1 Receptor Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Thyroid eye disease indication 276177000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Insulin-like growth factor 1 receptor Kinase ANTAGONIST IC50 9 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
Y64GQ0KC0A UNII
C2987429 UMLSCUI
CHEMBL1743079 ChEMBL_ID
DB06343 DRUGBANK_ID
C558734 MESH_SUPPLEMENTAL_RECORD_UI
D09680 KEGG_DRUG
10612 IUPHAR_LIGAND_ID
2274802 RXNORM
329754 MMSL
37968 MMSL
d09494 MMSL
840364008 SNOMEDCT_US
840397009 SNOMEDCT_US
4039110 VANDF
4039111 VANDF
018259 NDDF
C551399 MESH_SUPPLEMENTAL_RECORD_UI
9107 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TEPEZZA HUMAN PRESCRIPTION DRUG LABEL 1 75987-130 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS BLA 28 sections